Showing results (1-10 of 28) with videos related to
Sort By:
Pageof 3
Therapeutic Advances in Hematology|June 9, 2021
The role of axicabtagene ciloleucel as a treatment option for patients with follicular/marginal zone lymphomaJose Sandoval-Sus, Julio C ChavezCureus|December 23, 2022
Use of Mogamulizumab for Cutaneous Adult T-cell Leukemia in a Patient Living With HIVStephanie Boisclair, Amanda Brahim, Jose Sandoval-SusDrugs in Context|December 18, 2019
Drug therapy for double-hit lymphomaVania Phuoc, Jose Sandoval-Sus, Julio C ChavezCurrent Oncology Reports|May 31, 2022
Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed DiseaseMeri Tarockoff, Teresita Gonzalez, Stanislav Ivanov, et al.Expert Opinion on Biological Therapy|January 9, 2025
Should CAR-T cell therapy be considered a standard of care for patients with refractory diffuse large B-cell lymphoma in second line treatment?Lucia Perez-Lamas, Jose Sandoval-Sus, Julio C ChavezBMJ Case Reports|August 9, 2013
Vertebral osteomyelitis caused by Mycobacterium abscessusDaniel C Garcia, Jose Sandoval-Sus, Kanwal Razzaq, et al.Annals of Diagnostic Pathology|May 24, 2014
Progressive leukemic non-nodal mantle cell lymphoma associated with deletions of TP53, ATM, and/or 13q14Jennifer Chapman-Fredricks, Jose Sandoval-Sus, Francisco Vega, et al.International Journal of Hematologic Oncology|September 20, 2021
Anti-CD19 chimeric antigen receptor T-cell therapy in B-cell lymphomas: current status and future directionsJulio C Chavez, Farah Yassine, Jose Sandoval-Sus, et al.Critical Reviews in Oncology/Hematology|April 22, 2017
The role of anti-PD-1 and anti-PD-L1 agents in the treatment of diffuse large B-cell lymphoma: The future is nowLuis Miguel Juárez-Salcedo, Jose Sandoval-Sus, Lubomir Sokol, et al.International Journal of Molecular Sciences|February 24, 2024
Bruton's Tyrosine Kinase Inhibitors: Recent UpdatesAmneh Fares, Carlos Carracedo Uribe, Diana Martinez, et al.Pageof 3